

**Supplementary Table S6.** Studies investigating the association between IL-6 and CoVID-19 mortality with hazard ratio values.

Study, year	Study design	Crude HR (95% CI)	p value	Adjusted HR (95% CI)	p value	Adjusted for
<b>Abers MS 2021 [32]</b>	Cohort	1.87 (1.24–2.84)	0.0033	1.77 (1.24–2.52)	0.0015	Time to sampling, age, chronic kidney disease, and use of immunomodulatory medications prior to sample collection
<b>Avila-Nava A 2021 [41]</b>	Cohort	–	–	1.01 (1.003–1.020)	0.011	Age, gender, diabetes, hypertension
<b>Bai Y 2021 [42]</b>	Retrospective cohort	1.082 (1.055–1.110)	<0.001	1.085 (1.048–1.124)	<0.001	Age, sex, hypertension, diabetes, CHD, AF, CVD, COPD, CKD, malignancy, NLR, D-dimer, PTA, LDH, $\alpha$ -HBDH, ALB, DBIL, BUN, CysC, CRP
<b>Chen H 2021 [45]</b>	Cohort	–	–	1.001 (1.0003–1.002)	0.005	NEU, NLR, CRP, D-dimer, PT, MYO
<b>Donoso-Navarro E 2021 [47]</b>	Retrospective cohort	1.00094 (1.00054–1.0013)	<0.0001	1.0011 (1.001–1.0016)	<0.0001	Age, LDH, limfosit
<b>Li T 2021 [54]</b>	Retrospective cohort	1.02 (1.01–1.03)	<0.001	1.02 (1.01–1.04)	0.004	Age, CRP
<b>Ruscica M 2021 [59]</b>	Retrospective cohort	1.0033 (1.0014–1.0052)	0.001	–	–	–
<b>Trecarichi EM 2020 [61]</b>	Single-center, retrospective cohort	1.005 (1.002–1.008)	<0.001	1.005 (1.001–1.009)	0.007	Blood sodium level, lymphocytes, CVD other than hypertension
<b>Wang JH 2021 [36]</b>	Single-center, retrospective cohort	1.002 (1.002–1.002)	<0.001	–	–	–
<b>Wu C 2020 [36]</b>	Retrospective cohort	1.03 (1.01–1.05)	0.01	–	–	–
<b>Yang B 2021 [39]</b>	Cohort	1.001 (1.000–1.001)	<0.001	–	–	–